On September 22, 2020, Vogue featured insights from AFAR experts Nir Barzilai, MD, and David Sinclair, PhD, on the science driving what Vogue dubs as the “Longevity Movement.” Dr. Barzilai specifically highlights the potential of the Targeting Aging with Metformin (TAME) Trial to provide proof of concept that the biology of aging can be targeted in order to extend years of health and compress age-related co-morbidities.
Dr. Barzilai is AFAR’s Scientific Director, a 1994 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, a 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, a 2010 Irving S. Wright Award winner, and the Director at the Institute for Aging Research and distinguished Professor at the Albert Einstein College of Medicine.
Dr. Sinclair is an AFAR board member, a 2000 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, and a 2018 Irving S. Wright Award recipient. He is also a Professor in the Department of Genetics and co-Director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School.
Read the article, “Is Aging a Disease You Can Reverse? A Look at the Science Behind the Longevity Movement,” here.
